Oral contraceptives (OCs) increase risk of venous thromboembolic disease (VTE). The incidence of thomboembolic disease in healthy young women who are not taking OCs is 0.4-0.8/10,000, and in healthy young women using OCs, it is 3-4/10,000. To assess whether a family history of thromboembolism is a suitable tool to identify women who should not be given OCs, 50 women who suffered a VTE while taking OCs were studied. Only 16% of these women had family history which is why in our opinion, it is not a sufficient safeguard to recommending the use of OCs.
1. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet1994;344:1453-1453.
2.
2. Schambeck CHM, Schwender S, Haubitz I, et al. Selective screening for the factor V Leiden mutation: Is it advisable prior to the prescription of oral contraceptives?Thromb Haemost1997;78:1480-1480.
3.
3. Vandenbroucke JP, Van der Meer FJM, Helmerhorst FM, et al. Factor V Leiden: Should we screen oral contraceptive users and pregnant women?Br Med J1996; 313:1127-1127.
4.
4. Frezzato M, Tosetto A, Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J Epidemiol1996;143:1257-1257.
5.
5. Aznar J, Vaya A, Estelles A, et al. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives. Haematologica2000;85:1271-1271.
